Active, not recruitingPhase 2NCT04416568

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Studying Atypical teratoid rhabdoid tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Suzanne Forrest, MD
Dana-Farber Cancer Institute
Intervention
Nivolumab(drug)
Enrollment
45 enrolled
Eligibility
40 years · All sexes
Timeline
2020 – 2026

Study locations (8)

Collaborators

Gateway for Cancer Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04416568 on ClinicalTrials.gov

Other trials for Atypical teratoid rhabdoid tumor

Additional recruiting or active studies for the same condition.

See all trials for Atypical teratoid rhabdoid tumor →

← Back to all trials